Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy.


Journal

La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 18 07 2018
accepted: 14 03 2019
pubmed: 10 4 2019
medline: 11 10 2019
entrez: 10 4 2019
Statut: ppublish

Résumé

To assess the outcome of malignant pleural mesothelioma patients treated with extra-pleural pneumonectomy (EPP) and adjuvant radiotherapy (RT), using the most advanced radiotherapeutic techniques, namely image-guided intensity-modulated RT (IG-IMRT). Fifty-four patients were analyzed. Minimum radiation dose was 50 Gy (2 Gy/fr). Planning target volume encompassed the entire hemithorax, including the ipsilateral mediastinum if interested by disease, the pericardium and diaphragm, and any drain sites. The study endpoints included loco-regional control (LRC), distant metastases free survival (DMFS), and overall survival (OS), as well as radiation-related toxicity. Major patients and treatment characteristics were the following: median age 62 years, epithelioid histology in 51 (94%) cases, locally advanced disease in 41 (90%) cases, and metastatic mediastinal lymph nodes in 27 patients (50%). Only 7 patients (13%) had gross residual disease after surgery. Chemotherapy was administered in 38 patients (70%). Median follow-up was 16 months (range 0-73 months). Median and 2-year OS were 21 months and was 43.8%, respectively. The predominant pattern of failure was distant: 34 patients (62.9%) developed some component of distant failure, and only 5 patients (9.2%) developed an isolated loco-regional recurrence. The estimates of LRC and DMFS at 2 years were 63.4% and 43.4%, respectively. Three fatal pneumonitis were documented. Other major toxicities included: Grade 2 and 3 pneumonitis in 1 and 2 cases, respectively, 1 case of bronchial fistula, pleural empyema, and Grade 3 esophagitis, respectively. Although executed in the era of high-technology radiotherapy (IG-IMRT), EPP should not be routinely performed.

Identifiants

pubmed: 30963379
doi: 10.1007/s11547-019-01030-y
pii: 10.1007/s11547-019-01030-y
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

854-859

Références

Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):606-16
pubmed: 12573747
Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):768-75
pubmed: 12573764
Thorac Surg Clin. 2004 Nov;14(4):469-77, viii
pubmed: 15559053
J Thorac Cardiovasc Surg. 2008 Mar;135(3):620-6, 626.e1-3
pubmed: 18329481
J Clin Oncol. 2009 Mar 20;27(9):1413-8
pubmed: 19224855
J Clin Oncol. 2009 Jun 20;27(18):3007-13
pubmed: 19364962
Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):942-9
pubmed: 20381267
Lancet Oncol. 2011 Aug;12(8):763-72
pubmed: 21723781
Radiother Oncol. 2011 Nov;101(2):303-6
pubmed: 21864923
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):362-8
pubmed: 22516382
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1278-83
pubmed: 22607910
J Thorac Oncol. 2013 Feb;8(2):238-45
pubmed: 23247629
Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):606-13
pubmed: 26281826
Ann Thorac Surg. 2015 Sep;100(3):1133
pubmed: 26354657
Lancet Oncol. 2015 Dec;16(16):1651-8
pubmed: 26538423
Radiat Oncol. 2015 Dec 30;10:267
pubmed: 26715491
Eur J Cardiothorac Surg. 2017 Nov 1;52(5):975-981
pubmed: 28482086
J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5
pubmed: 9869758

Auteurs

Marco Trovo (M)

Department of Radiation Oncology, Azienda Sanitaria Universitaria Integrata Udine, P.le Santa Maria della Misericordia 15, 33100, Udine, Italy.

Davide Franceschini (D)

Department of Radiotherapy and Radiosurgery, Humanitas Cancer Center and Research Hospital, Rozzano, Via Manzoni 56, Rozzano, Milan, Italy.

Carlo Furlan (C)

Department of Radiation Oncology, Ospedale San Martino di Belluno, Viale Europa 22, 32100, Belluno, Italy.

Francesca Pietrobon (F)

Department of Radiation Oncology, Ospedale San Martino di Belluno, Viale Europa 22, 32100, Belluno, Italy.

Stefano Vagge (S)

Department of Radiation Oncology, Azienda Ospedaliera Universitaria San Martino di Genova - IST, Istituto Nazionale Ricerca sul Cancro, Largo Rosanna Benzi, 10, 16132, Genoa, Italy.

Eleonora Farina (E)

Radiation Oncology Department, National Cancer Institute, CRO IRCCS, Via Franco Gallini, 2, 33081, Aviano, PN, Italy.

Alberto Revelant (A)

Radiation Oncology Department, National Cancer Institute, CRO IRCCS, Via Franco Gallini, 2, 33081, Aviano, PN, Italy.

Luca Visani (L)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Largo Brambilla, 3, 50134, Florence, Italy.

Virginia Maragna (V)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Largo Brambilla, 3, 50134, Florence, Italy.

Giuseppe Parisi (G)

Department of Radiation Oncology, Azienda Sanitaria Universitaria Integrata Udine, P.le Santa Maria della Misericordia 15, 33100, Udine, Italy. giuseppe.parisi@asuiud.sanita.fvg.it.

Vieri Scotti (V)

Department of Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Largo Brambilla, 3, 50134, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH